GlassScriptPhysician profile
Terri Jo Agan
NPI 1659335974
$4,538.65
in general payments reported to CMS, 2019-2025
31 companies · $832 in 2025
The $832 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $658 · 2022: $956 · 2023: $1,311 · 2024: $782 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,888 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.50 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $858.58 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $830.93 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $451.46 | 2021-2025 | Farxiga, Bevespi Aerosphere, Fasenra |
| Glaxosmithkline, LLC. | $354.83 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $302.13 | 2022-2025 | |
| Pfizer INC. | $231.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.95 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $204.56 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $143.23 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Cequr Corporation | $109.69 | 2023 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $108.24 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $85.50 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Dexcom, INC. | $79.56 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.88 | 2022-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $56.64 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.54 | 2021-2022 | |
| Exact Sciences Corporation | $49.81 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $45.60 | 2021-2023 | |
| Amgen INC. | $41.82 | 2021-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $40.91 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.07 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $30.33 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $23.14 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $21.23 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.10 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $16.42 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $15.45 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.14 | 2025 | Fanapt |
| Astellas Pharma US INC | $13.14 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $12.70 | 2021 | |
| Mayne Pharma Commercial LLC | $6.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Agan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.